Loading clinical trials...
Loading clinical trials...
Phase 3 Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
Conditions
Interventions
CP-690,550
CP-690,550
+6 more
Locations
115
United States
Pfizer Investigational Site
Huntsville, Alabama, United States
Pfizer Investigational Site
Tucson, Arizona, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
Santa Maria, California, United States
Pfizer Investigational Site
Colorado Springs, Colorado, United States
Pfizer Investigational Site
Gainesville, Florida, United States
Start Date
March 1, 2009
Primary Completion Date
April 1, 2011
Completion Date
February 1, 2012
Last Updated
May 16, 2024
NCT07017686
NCT05038553
NCT05790356
NCT03429426
NCT06028438
NCT06800157
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions